PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials

Abstract Background Ovarian cancer is the eighth leading cause of cancer-related death among women, characterized by late diagnosis and a high relapse rate. In randomized controlled trials, we aimed to evaluate the efficacy and safety of PARP inhibitors (PARPi) in treating advanced ovarian cancer. M...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	István Baradács, Brigitta Teutsch, Alex Váradi, Alexandra Bilá, Ádám Vincze, Péter Hegyi, Tamás Fazekas, Balázs Komoróczy, Péter Nyirády, Nándor Ács, Ferenc Bánhidy, Balázs Lintner
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2024-02-01
Schriftenreihe:	Journal of Ovarian Research
Schlagworte:	Olaparib Niraparib Rucaparib HRD Homologous recombination repair
Online-Zugang:	https://doi.org/10.1186/s13048-024-01362-y
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!